A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab

Case Rep Oncol. 2022 Nov 28;15(3):1063-1073. doi: 10.1159/000527205. eCollection 2022 Sep-Dec.

Abstract

Lung cancer is one of the most common cancers and has the highest risk of mortality in both genders. This devastating cancer is also a significant financial and emotional burden to patients and the healthcare system. Chemotherapy and immunotherapy have become the cornerstone for the treatment of lung cancer. However, treatment may come with severe and sometimes fatal side effects. In this report, we present the case of a 52-year-old Caucasian male who suffered two episodes of prolonged cardiac arrest after the infusion of paclitaxel and pembrolizumab.

Keywords: Cardiotoxicity; Chemotherapy; Immunotherapy; Lung cancer.

Publication types

  • Case Reports

Grants and funding

This study was supported by K12CA090628 (Yanyan Lou). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.